Although further studies, especially in the form of clinical trials, are needed to clarify the safety and optimize the administration schedule of PRMT5 inhibitors, the present study indicates that therapeutic strategies targeting PRMT5 are of considerable interest for chronic heart failure therapy. The gene discussed is PRMT5; the disease is congestive heart failure.